Are you Dr. Naficy?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 20 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
15 Highland St
Unit 204
West Hartford, CT 06119Phone+1 860-231-9491
Summary
- Dr. Abdollah Naficy, MD is an infectious disease specialist in West Hartford, Connecticut. He is currently licensed to practice medicine in District of Columbia, California, and New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 1988 - 1990
New York Downtown HospitalResidency, Internal Medicine, 1986 - 1988
University of London Faculty of MedicineClass of 1982
Certifications & Licensure
CA State Medical License 1992 - 2024
DC State Medical License 1998 - 2024
NY State Medical License 1988 - 2007- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- 190 citationsA chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial.Raffael Nachbagauer, Jodi Feser, Abdollah Naficy, David I. Bernstein, Jeffrey T. Guptill
Nature Medicine. 2021-01-01 - 89 citationsImmunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I. Bernstein, Jeffrey T. Guptill, Abdollah Naficy, Raffael Nachbagauer, Francesco Berlanda-Scorza
The Lancet. Infectious Diseases. 2020-01-01 - 63 citationsHigh Disease Burden of Diarrhea Due to Enterotoxigenic Escherichia coli among Rural Egyptian Infants and Young ChildrenMalla R. Rao, Remon Abu-Elyazeed, Stephen J. Savarino, Abdollah Naficy, Thomas F. Wierzba
Journal of Clinical Microbiology. 2003-10-01
Press Mentions
A Chimeric Hemagglutinin-Based Universal Influenza Virus Vaccine Approach Induces Broad and Long-Lasting Immunity in a Randomized, Placebo-Controlled Phase I TrialDecember 7th, 2020
